T. Rowe Price Associates’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.95M | Sell |
361,441
-7,213
| -2% | -$98.8K | ﹤0.01% | 1267 |
|
|
2025
Q1 | $4.08M | Sell |
368,654
-25,330
| -6% | -$280K | ﹤0.01% | 1308 |
|
|
2024
Q4 | $4.2M | Buy |
393,984
+381,145
| +2,969% | +$4.06M | ﹤0.01% | 1326 |
|
|
2024
Q3 | $164K | Buy |
12,839
+1,891
| +17% | +$24.2K | ﹤0.01% | 2713 |
|
|
2024
Q2 | $184K | Sell |
10,948
-256,195
| -96% | -$4.31M | ﹤0.01% | 2611 |
|
|
2024
Q1 | $4.01M | Buy |
+267,143
| New | +$4.01M | ﹤0.01% | 1281 |
|